Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk of coronary heart disease in the 76-week, placebo-controlled, Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib (DEFINE) trial. Here, we report the results of the 2-year extension to the DEFINE study where patients (n = 803) continued on the same assigned treatment as in the original 76-week study. Treatment with anacetrapib during the 2-year extension was well tolerated with a safety profile similar to patients on placebo. No clinically important abnormalities in liver enzymes, blood pressure, electrolytes, or adverse experiences were observed during the extension. At the end of the extension study, relative to the original baseline value, anacetrapib reduced Friedewald-calculated LDL-C by 39.9% and increased HDL-C by 153.3%, compared to placebo. The apparent steady state mean plasma trough concentration of anacetrapib was ∼640 nmol/L. Geometric mean plasma concentrations of anacetrapib did not appear to increase beyond week 40 of the 2-year extension of the 76-week DEFINE base study. In conclusion, an additional 2 years of treatment with anacetrapib were well tolerated with durable lipid-modifying effects on LDL-C and HDL-C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · cited 4×
“The 76-week, placebo-controlled, Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib (DEFINE) study evaluated the effects of anacetrapib versus placebo on safety and lipid parameters in patients with coronary heart disease (CHD) or at high risk of CHD, who were treated with statins + other li…”
BackgroundMethodSelf-citationGotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86 · cited 1×
“Following this base study, there was an off-drug reversibility period of at least 12 and up to 24 weeks duration.(5) A total of 1211 patients completed the base study including the reversibility period (n 1⁄4 548 on anacetrapib, n 1⁄4 663 on placebo).”
BackgroundSelf-citationMeasurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56 · cited 1×
“A subsequent analysis showed that compared to the reference b-quantification method, the Friedewald equation underestimates LDL-C levels after treatment with anacetrapib, so that the actual degree of LDL-C reduction may have been less than originally reported.(3) A 2-year extension to the DEFINE study was conducted to…”
ResultSelf-citation
Cited by
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“Patients who completed follow-up of DEFINE’s reversibility phase were eligible for the DEFINE 2-year extension study to assess longer-term safety and lipid effects (34).”
MethodNational lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Metadata
- Authors
- Gotto, A. M., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P., & the DEFINE Investigators
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2014-04-14
- Volume
- 19
- Issue
- 6
- Pages
- 543-549
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2091883594
- Cited by
- 45
- References
- 3
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. https://app.cochat.ai/papers/10.1177/1074248414529621
- The paper
- Gotto, A. M., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., Dansky, H. M., Mitchel, Y., Barter, P., & the DEFINE Investigators. (2014). Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/1074248414529621
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.